Research Papers:

YAP1 acts as oncogenic target of 11q22 amplification in multiple cancer subtypes.

Erica Lorenzetto, Monica Brenca, Mattia Boeri, Carla Verri, Elena Piccinin, Patrizia Gasparini, Federica Facchinetti, Sabrina Rossi, Giuliana Salvatore, Maura Massimino, Gabriella Sozzi, Roberta Maestro and Piergiorgio Modena _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2014; 5:2608-2621. https://doi.org/10.18632/oncotarget.1844

Metrics: PDF 3221 views  |   HTML 3384 views  |   ?  


Erica Lorenzetto1, Monica Brenca1, Mattia Boeri2, Carla Verri2, Elena Piccinin1, Patrizia Gasparini2, Federica Facchinetti2, Sabrina Rossi3, Giuliana Salvatore4, Maura Massimino5, Gabriella Sozzi2, Roberta Maestro1, Piergiorgio Modena6

1 Experimental Oncology 1, Aviano National Cancer Institute, Aviano (PN), Italy.

2 Tumor Genomics Laboratory, Milan National Cancer Institute, Milan, Italy.

3 Department of Pathology, Treviso General Hospital, Treviso, Italy.

4 Department of Biology and Cellular and Molecular Pathology, University Federico II, Naples, Italy.

5 Unit of Pediatric Oncology, Milan National Cancer Institute, Milan, Italy.

6 Laboratory of Human Genetics, Sant’ Anna General Hospital, San Fermo della Battaglia (Como), Italy.


Piergiorgio Modena, email:

Keywords: YAP1. Gene amplification. Salvador-Warts-Hippo pathway. Lung cancer. Cervical cancer. Oncogene.

Received: February 4, 2014 Accepted: March 21, 2014 Published: March 23, 2014


The transcriptional coactivator YAP1 is a critical effector of the human Salvador-Warts-Hippo pathway. Literature data report apparently discrepant results on the carcinogenic role of YAP1, which acts either as oncogene or as tumor suppressor in different in vitro and in vivo models. Furthermore, genomic amplification events of 11q22 locus encompassing YAP1 gene have been detected in multiple tumor types but there is limited direct evidence about the oncogenic role of endogenous YAP1 within in the amplicon.

We screened a panel of human tumor samples and cancer cell lines and identified that the YAP1 amplification event is actually present in up to 23% of the cases. We exploited EKVX (lung cancer), CaSki (cervical cancer) and RO82 (thyroid cancer) cell lines harboring both genomic YAP1 amplification and YAP1 protein overexpression, in order to study the effects of downregulation of endogenous YAP1 by RNA-interference strategies. Class comparison analysis of gene expression profiling data identified 707 statistically significantly modulated genes (multivariable global test p-value = 0.002) that were functionally annotated for cell proliferation and cellular movement ontologies. Mechanistic studies of the identified perturbed pathways revealed that YAP1 silencing significantly decreased cell proliferation and cell cycle perturbation associated with upregulation of p21 and p27 cell-cycle inhibitors, reduced cell migration (p<0.048) and anchorage-independent growth (p<0.02). In CaSki cell line, YAP1 silencing induced significantly increased sensitivity and cell-death response to cisplatin treatment (p=0.011) as well as reduction of in-vivo tumorigenic potential (p=0.027).

Overall, these results establish that YAP1 is a direct oncogenic target of the 11q22 amplicon in previously unreported cancer types and support the relevance of such genetic aberration in carcinogenesis in a fraction of multiple tumor types.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 1844